Pre-market · Regular session opens 9:30 AM ET
Last update: Aug 11, 2026, 6:28 PM ET
Belite Bio, Inc
$177.58 6.17% today
Pre-market

Why Belite Bio, Inc (BLTE) stock moved

Updated Aug 12, 2026

Belite Bio, Inc (BLTE) shares climbed 6.2% to $177.58 as of August 12, 2026, a significant gain from the prior close of $167.26. BestStocks flagged the session as a major change for BLTE. The move is tied to price move up. Below, we break down what changed for BLTE, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

BLTE climbed 6.2% to $177.58

BLTE climbed 6.2% in its latest session, moving from $167.26 to $177.58.

Material / EarningsMedium confidence
Rel. volume
1.3×
Normal
Vs peers
No comparable peers
Market cap
$7.1B
NASDAQ Capital Market
Analyst target
$212
+19.5% vs price
Price chart
Jul 13 – Aug 12
EVVEEVE$146$162$178Jul 13Jul 21Jul 28Aug 5Aug 12
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Belite Bio, Inc investors

For Belite Bio, Inc investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 6.2% price move. Weighing against that: Belite Bio, Inc (BLTE) moved -2.66% from $161.43 to $157.14 on 2026-07-22; Belite Bio, Inc (BLTE) moved -2.55% from $153.24 to $149.33 on 2026-07-10. Wall Street's consensus price target sits at $212.25, implying +19.5% upside from $177.58. BestStocks rates the overall signal quality medium (61/100). With earnings roughly 1 days out, the next report is the most likely near-term test of the move.

BLTE price reaction

BLTE last traded at $177.58, up $10.32 (+6.17%) from the previous close of $167.26. The session traded on 1.3× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $146.68 and $177.58, and it currently sits about 100% of the way up that band.

Bullish and bearish analyst opinions on Belite Bio, Inc (BLTE)

The consensus analyst price target on Belite Bio, Inc (BLTE) is $212.25, 19.5% above the recent $177.58. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on BLTE line up.

The bullish case

  • Wall Street's consensus price target of $212.25 implies +19.5% upside from $177.58.
  • The Street's most bullish target is $217.00 (+22.2%).
  • Material positive event.
  • Strong 6.2% price move.
  • Belite Bio, Inc (BLTE) moved +2.31% from $163.48 to $167.26 on 2026-08-10, reaching a new 30-day high.

The bearish case

  • Belite Bio, Inc (BLTE) moved -2.66% from $161.43 to $157.14 on 2026-07-22.
  • BLTE moved -3.42% from $157.69 to $152.30 on 2026-07-08.
Bull vs bear balanceBullish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Aug 12, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $212+19.5%
= 3 maintains
HC Wainwright & Co. maintained Buy · 2026-06-15
SEC filings watch
No recent filings
Peer context
BLTE+6.2%

Previous notable changes for BLTE

Activity2026-08-10+2.6%
Belite Bio, Inc (BLTE) moved +2.31% from $163.48 to $167.26 on 2026-08-10, reaching a new 30-day high. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-07+1.5%
Belite Bio, Inc (BLTE) moved +0.85% from $161.67 to $163.05 on 2026-08-07, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Material / Earnings2026-07-30+4.9%
Belite Bio, Inc (BLTE) moved +4.36% from $153.24 to $159.92 on 2026-07-30. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.5x the 5-day average, modestly elevated.
Material / Earnings2026-07-27+3.3%
Belite Bio, Inc (BLTE) moved +2.66% from $154.33 to $158.43 on 2026-07-27. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Trading volume was near its 5-day average.
Upcoming catalysts & outlook
Next earnings
2026-08-13 (est.)
in 1 days
Thesis shift
Bullish Shift
bullish signal
Risk level
High
from change events

Frequently asked questions about BLTE

Why did Belite Bio, Inc (BLTE) stock move?

BLTE climbed 6.2% to $177.58. No single company-specific catalyst was confirmed during the move window, and it looks technical.

How much did BLTE stock rise?

BLTE gained 6.17% ($10.32) versus the prior close of $167.26, last trading at $177.58 on 1.3× average volume.

When is Belite Bio, Inc's next earnings date?

BLTE's next earnings report is estimated for 2026-08-13 — about 1 day away.

What is the analyst price target for BLTE?

The consensus analyst price target for BLTE is $212.25, about 19.5% above the current $177.58. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 0 downgrades.

How BestStocks tracks BLTE

This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 14 tracked change events for BLTE, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 12, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.